Viracta Therapeutics, Inc. VIRX
At closeJul 2, 2026, 4:00 PM EDT
After hours · Jul 2, 4:00 PM ET
- YTD
- -93.92%
- 1 year
- -93.89%
- Market cap
- 9.25M
- EPS (ttm)
- -1.10
- Shares out
- 39.74M
- Forward P/E
- -0.38
- YTD return
- -93.92%
- 1-year return
- -93.89%
- Avg volume
- 2.19M
- Open
- 0.00978
- Previous close
- 0.00978
- Day's range
- 0.00978 – 0.00978
- 52-week range
- 0.13 – 1.31
- Beta
- 0.30
- Price target
- 3.00 (+30574.8%)
Key statistics
- Enterprise value
- 489.97K
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.71
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -26.06M
- Total cash
- 30.00M
- Total debt
- 18.82M
- Return on equity
- -208.67%
- Short % of float
- 8.68%
- 50-day average
- 0.1908
- 200-day average
- 0.49815
Analyst view
- Strong buy0
- Buy0
- Hold1
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.195.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -0.21 | -0.27 | -0.06 | -28.57% |
| Aug 14, 2024 | Jun 1, 2024 | -0.35 | -0.25 | +0.10 | +28.57% |
| May 9, 2024 | Mar 1, 2024 | -0.35 | -0.23 | +0.12 | +34.29% |
| Mar 7, 2024 | Dec 1, 2023 | -0.30 | -0.35 | -0.05 | -16.67% |
| Nov 9, 2023 | Sep 1, 2023 | -0.33 | -0.33 | 0.00 | 0.00% |
| Aug 14, 2023 | Jun 1, 2023 | -0.30 | -0.32 | -0.02 | -6.67% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 14, 2024 | RBC Capital | main | Outperform | Outperform |
| Aug 16, 2024 | Leerink Partners | down | Outperform | Market Perform |
| Aug 15, 2024 | RBC Capital | main | Outperform | Outperform |
| May 23, 2024 | Oppenheimer | main | Outperform | Outperform |
| Apr 17, 2024 | Oppenheimer | main | Outperform | Outperform |
| Apr 16, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Viracta Therapeutics, Inc.
Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company's Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- viracta.com
News
Viracta Therapeutics Announces Wind Down of Operations 
12 Health Care Stocks Moving In Monday's Pre-Market Session - 12 Health Care Stocks Moving In Monday's Pre-Market Session
Why Triumph Group Shares Are Trading Higher By Over 36%; Here Are 20 Stocks Moving Premarket 
12 Health Care Stocks Moving In Friday's Pre-Market Session 
Masimo To Rally More Than 13%? Here Are 5 Top Analyst Forecasts For Friday - Why Evaxion Biotech Shares Are Trading Higher By Around 62%; Here Are 20 Stocks Moving Premarket
Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives 
12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
Why Marvell Technology Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Your note
Sign in to keep a note on VIRX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHEVALLARD DANIEL R | Chief Operating Officer | Sale | Feb 26, 2024 | 102,306 |
| POMERANTZ ROGER J | Director | Conversion of Exercise of derivative security | Nov 24, 2024 | 126,478 |
| ROJKJAER LISA | Officer | Sale | Feb 26, 2023 | 48,087 |
| ROTHERA MARK | Chief Executive Officer | Purchase | Nov 30, 2023 | 100,000 |
| ROYSTON IVOR | Director | Conversion of Exercise of derivative security | Nov 24, 2024 | 858,340 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Citadel Advisors Llc | 3.83% | 1,520,240 | 353.76K | Sep 29, 2024 |
| Vanguard Group Inc | 2.40% | 954,485 | 222.11K | Sep 29, 2024 |
| Samsara BioCapital, LLC | 1.74% | 689,709 | 160.50K | Sep 29, 2024 |
| Stonepine Capital Management, LLC | 1.26% | 500,000 | 116.35K | Sep 29, 2024 |
| Laurion Capital Management, LP | 0.84% | 332,189 | 77.30K | Sep 29, 2024 |
| Aisling Capital Management LP | 0.73% | 288,571 | 67.15K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.64% | 652,914 | 151.93K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.71% | 282,488 | 65.73K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.36% | 142,083 | 33.06K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.10% | 41,223 | 9.59K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.07% | 28,467 | 6.62K | Oct 30, 2024 |
| Vanguard Institutional Index-Inst Total Stock Market Ind | 0.05% | 20,521 | 4.78K | Sep 29, 2024 |